1. Home
  2. LOAN vs EQ Comparison

LOAN vs EQ Comparison

Compare LOAN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.71

Market Cap

51.9M

Sector

Real Estate

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.54

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
EQ
Founded
1989
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.9M
57.8M
IPO Year
1999
2018

Fundamental Metrics

Financial Performance
Metric
LOAN
EQ
Price
$4.71
$1.54
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
28.2K
882.5K
Earning Date
10-24-2025
11-13-2025
Dividend Yield
9.58%
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
$7,138,128.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$10.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.29
$0.27
52 Week High
$6.05
$2.35

Technical Indicators

Market Signals
Indicator
LOAN
EQ
Relative Strength Index (RSI) 39.85 63.04
Support Level $4.80 $1.04
Resistance Level $4.98 $1.71
Average True Range (ATR) 0.14 0.22
MACD -0.01 0.05
Stochastic Oscillator 7.48 75.47

Price Performance

Historical Comparison
LOAN
EQ

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: